MetaVia (NASDAQ:MTVA) Price Target Lowered to $3.00 at Maxim Group

MetaVia (NASDAQ:MTVA) had its target price lowered by equities research analysts at Maxim Group from $6.00 to $3.00 in a research note issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. Maxim Group’s price target indicates a potential upside of 334.47% from the stock’s current price.

Separately, HC Wainwright reissued a “buy” rating and issued a $12.00 target price on shares of MetaVia in a report on Wednesday, April 16th.

MetaVia Price Performance

MTVA stock opened at $0.69 on Monday. MetaVia has a 12 month low of $0.65 and a 12 month high of $5.30. The business has a 50-day moving average of $1.11.

MetaVia (NASDAQ:MTVA) last posted its earnings results on Wednesday, May 14th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.21. As a group, analysts anticipate that MetaVia will post -3.9 EPS for the current year.

MetaVia Company Profile

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.